August 18th in Ft. Myers, Fl. – MS Treatment Strategies & Therapeutic Symptom Management
Register for this program by…
EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
LUND, SWEDEN, Jul 17, 2012 — Active Biotech today announced that the European Medicines Agency (EMA) has completed the validation…
Stuart Schlossman
FREE Multiple Sclerosis Education program on September 8, 2012 in Jacksonville, Florida
For SEPTEMBER 8th, 2012 Invites you to an informative education program “Treatment Strategies, Symptom Management” & the Urological Implications of…
Stuart Schlossman
With help from the DoD, Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
MENLO PARK, Calif., July 10, 2012 /PRNewswire via COMTEX/ — The Department of Defense (DoD) has awarded SRI International a…
Stuart Schlossman
Neuroprotective effects underpin fingolimod benefits in MS
July 10, 2012 – By Eleanor McDermid Fingolimod therapy reduces inflammatory activity and tissue loss in the brains of patients with multiple…
Stuart Schlossman
Biogen Idec Patient Resources
As part of our ongoing commitment to patients, Biogen Idec provides a variety of support services for patients and caregivers…
Stuart Schlossman
Novartis adds details on heart safety and monitoring to label of its MS drug Gilenya
April 20, 2012 NEW YORK (AP) — Swiss drugmaker Novartis AG said Friday it is updating the label on its…
Stuart Schlossman
Patient on Novartis’ multiple sclerosis drug gets rare brain disease – PML…
Published April 13, 2012 The Wall Street Journal BASEL, Switzerland – Novartis said Friday a patient treated with its multiple…
Stuart Schlossman
Synthetic Biologics — formerly Adeona Pharmaceuticals — set to start phase-two test of multiple sclerosis drug
Ann Arbor-based Synthetic Biologics Inc., formerly known as Adeona Pharmaceuticals Inc., announced today that it has completed enrollment of 164 patients for…
Stuart Schlossman
Back on Track: Phase III Study of Teva’s Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients
March 15, 2012 Phase III ALLEGRO study results showed laquinimod reduced the annual rate of relapses, slowed the progression of…
Stuart Schlossman
